Berdazimer gel 10.3%,
does it really help with Complete molluscum lesion clearance at week 12?
research showsGrade C. Complete clearance occurred in 144/444 (32.4%) versus 88/447 (19.7%), an absolute difference of +12.7 points; adjusted OR 2.0 (95% CI 1.5-2.8), P<.001. The endpoint was lesion count and the pivotal evidence is one Novan-sponsored trial.
ads claimZelsuvmi was approved in the US in 2024; Korean approval and sale could not be confirmed. Molluscum is treated in Korea, which is not evidence of domestic product availability.
Useful facts when choosing a product
- Once-daily treatment for 12 weeks was tested at 55 US sites.
- Molluscum may resolve naturally; 19.7% cleared with vehicle.
What the research actually shows
Axis 6 B0 evidence ① Allocation concealment: "The randomization schedule was generated by an independent statistician." ② Blinding: "double-blind" with matching study gels. ③ Analysis set and missingness: "patients with missing lesion count data at week 12 were counted as nonresponders." ④ Prespecified primary endpoint: "The primary efficacy end point was complete clearance of all MC lesions at week 12." - consistent with NCT04535531
Four gates: ① Defect: none. ② Listed item: none. ③ Evidence: independent schedule, double blinding, nonresponder imputation, and registered primary outcome. ④ Avoidability: no confirmed avoidable defect.
Why this is classified as C (54)
A positive large double-blind RCT is limited by a surrogate endpoint, manufacturer funding, and no independent replication, giving C with 54 points.
Counterpoint. Local pain and erythema and natural history matter to individual decisions.
Rejudgment record. Source verified — Positive large double-blind RCT with a lesion-count surrogate and manufacturer-only evidence
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Complete lesion clearance at week 12 | C | The absolute difference was +12.7 points. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | 55-site double-blind vehicle-controlled phase 3 randomized trial | 447 | Sponsored by Novan Inc; multiple authors were employees or equity holders | Complete clearance of all lesions at week 12 | 144/444 (32.4%) versus 88/447 (19.7%), absolute difference +12.7 points, adjusted OR 2.0 (95% CI 1.5-2.8), P<.001 | Single manufacturer-sponsored confirmatory trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of Berdazimer Gel for Complete Lesion Clearance in Molluscum Contagiosum at Week 12, a Surrogate Outcome — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/berdazimer-gel-molluscum-complete-clearance-week-12/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.